statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%

EFFECTOR Therapeutics shares are trading lower by 74% during Monday's session. The company announced that it has terminated its employees and will wind down its operations.
read more...

eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator...

eFFECTOR Therapeutics trading halted, news pending

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

eFFECTOR Therapeutics trading resumes

eFFECTOR Therapeutics (NASDAQ:EFTR) Stock Rating Reaffirmed by HC Wainwright

eFFECTOR Therapeutics (NASDAQ:EFTR - Get Free Report)s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on...

eFFECTOR Therapeutics (NASDAQ:EFTR) Earns Buy Rating from HC Wainwright

eFFECTOR Therapeutics (NASDAQ:EFTR  Get Free Report)s stock had its buy rating reissued by equities researchers at HC Wainwright in a note issued to investors on Thursday...

Buy Rating for eFFECTOR Therapeutics Backed by Solid Financials and Promising Zotatifin Trials

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on eFFECTOR Therapeutics (EFTR Research Report). The associated price ta...

eFfector Therapeutics reports Q4 EPS ($3.42), consensus ($1.65)

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024 Median progression free...

eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator...

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The company was founded by Kevan Shokat, Davide Ruggero, and Siegfried Reich on May 1, 2012 and is headquartered in Solana Beach, CA.

Volume	24,738.00
52-Wk High	$20.40
52-Wk Low	$0.032

EFTR eFFECTOR Therapeutics Inc

About

Feed

News

Earnings

Fundamentals